Expanding Access To Medicines: What Role For Transparency? 25/05/2017 by Mara Pillinger for Intellectual Property Watch 1 Comment Transparency” and “accountability” are familiar buzzwords. Like salt and pepper, they pop up on nearly every list of ingredients for sound policy and good governance. But, as Ilona Kickbusch and Suerie Moon of the Graduate Institute Global Health Centre in Geneva point out, their details are rarely specified: transparency for what? Accountability to whom? On Tuesday afternoon, those not busy casting a vote for the next World Health Organization director general got the chance to dig into these questions at a panel co-sponsored by the Graduate Institute and FIND. In particular, discussion focused on transparency in terms of public access to two types of information: drug R&D costs and clinical trial data.
WIPO Development And IP Committee Approves, Extends Projects Kicking Off New Era 25/05/2017 by Elise De Geyter for Intellectual Property Watch Leave a Comment The World Intellectual Property Organization Committee on Development and IP (CDIP) last week approved and extended a project implementing the WIPO Development Agenda in the areas of design protection, and a “game-changer” IP management and technology transfer project, and a conference for least-developed countries on copyright.
Beyond The Obvious – Direct And Indirect Territorial Coverage Of MPP/ViiV Voluntary License For Dolutegravir 24/05/2017 by Brook Baker for Intellectual Property Watch 2 Comments Pursuant to a license negotiated by the Medicines Patent Pool (MPP) with ViiV Healthcare (ViiV), an important new antiretroviral medicine, dolutegravir (DTG), will soon be available via generic competition in all low- and lower-middle-income countries, and a significant number of upper-middle-income countries as well. DTG is a highly recommended integrase inhibitor which highly effective, durable, inexpensive to produce, and relatively safe with few side effects. It is already an alternative WHO recommended first-line medicine and will probably become the global standard of care following trials on use of DTG to treat pregnant women and people with TB.[1] But until the MPP can succeed in getting inclusive licensing terms covering all low- and middle-income countries (LMICs), this unique clause in the MPP-ViiV license should be adopted in future licenses, as it is a best practice to date in terms of expansive coverage, writes Brook Baker.
Tedros Warms Up To Press In First Meeting, Sees Clear Mandate In “Landslide” Victory 24/05/2017 by William New, Intellectual Property Watch 2 Comments In his first meeting with the United Nations press corps the morning after his historic election as the next director general of the World Health Organization, Tedros Adhanom Ghebreyesus began to unfold his vision for the organisation and fended off questions about the United States budget by saying WHO has to diversify its funding base. He also signaled a variety of possible issues to come such as increased assessments on governments, and consideration of the recommendations of a recent UN report on access to medicines.
New Draft Decision Seeks To Deepen Analysis On WHO Pandemic Flu Framework 24/05/2017 by Catherine Saez, Intellectual Property Watch Leave a Comment A new draft decision submitted this week at the World Health Assembly (WHA) by a group of countries would set out further actions to analyse the Pandemic Influenza Preparedness (PIP) Framework.
Antimicrobial Resistance Needs New R&D Models, NGOs Say 24/05/2017 by Catherine Saez, Intellectual Property Watch 1 Comment A group of non-governmental organisations organised a side event to the World Health Assembly to discuss the growing issue of antimicrobial resistance, the way to incentivise research and development for new antibiotics, and the imperative of affordability and accessibility of new products. The speakers mentioned alternative models, such as delinking the cost of research from the price of the medicines, underlined the high prices of vaccines, and the importance of systems of infection prevention and control.
NCD Alliance Event: Time For Action Against Noncommunicable Diseases 24/05/2017 by Elise De Geyter for Intellectual Property Watch Leave a Comment It might be said it is a “golden moment” for fighting noncommunicable diseases. There have never been as many side events on noncommunicable diseases during the World Health Assembly as this year, according to speakers at an event of the NCD Alliance this week.
Ethiopian Becomes First African Head Of World Health Organization 23/05/2017 by William New, Intellectual Property Watch 2 Comments In a novel election process for the first time involving the full organisation membership, Tedros Adhanom Ghebreyesus of Ethiopia this evening was elected as the next director general of the World Health Organization, becoming the first official from Africa to be chosen to head the United Nations health agency.
Speculation Rampant In Leadup To WHO Director General Election Today 23/05/2017 by William New, Intellectual Property Watch Leave a Comment Speculation in the hallways of United Nations headquarters in Geneva was rampant in the days and hours leading up to this afternoon’s election of a new director general to lead the UN World Health Organization, but solid information about who will win was hard to come by. The outcome after a series votes is expected sometime tonight. Update! According to sources, the first round of voting is over. Results: Tedros 95, Nabarro 52, Nishtar 38. Second round update! Tedros 121, Nabarro 62. Third round underway.
US Supreme Court Puts New Limits On Patent Suits 23/05/2017 by Steven Seidenberg for Intellectual Property Watch Leave a Comment Yesterday’s United States Supreme Court decision in TC Heartland LLC v. Kraft Food Brands Group followed some familiar trends in Supreme Court jurisprudence. It overturned long-established Federal Circuit law, restricted the power of patent owners, and handed a stinging defeat to so-called “patent trolls” (companies that make money primarily by licensing their patents and suing those who refuse to purchase licenses). The Court did all this by limiting where patent infringement suits can be filed – and thus significantly changing patent litigation in the US.